Although the androgen receptor (AR) is the most important treatment target for prostate cancer, with the widespread use of Enzalutamide, an increasing number of patients receiving androgen deprivation treatment (ADT) have progressed to the CRPC stage [3–5]. The gene discussed is AR; the disease is prostate cancer.